177 Lu-labeled albumin-binder-conjugated PSMA-617 derivatives (University of British Columbia)

N/A

Report date: 2025/11/20 16:03:46

Base Information

Drug Name177 Lu-labeled albumin-binder-conjugated PSMA-617 derivatives (University of British Columbia)

Drug Alias NameLutetium-177-HTK-01169[177Lu]HTK-01169[177Lu]HTK-01169 (University of British Columbia)[177Lu]HTK03121[177-Lu]HTK03123 +[6]

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionSerum albumin modulatorsProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane AntigenSerum albumin

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of British Columbia

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of British Columbia

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A